Product image of Metamizol Basi (Metamizole Sodium Monohydrate) supplied by GNH India

Metamizol Basi

Active Ingredient:
Metamizole Sodium Monohydrate
Origin:
EU

Metamizol Basi (Metamizole Sodium Monohydrate)

Metamizole sodium, the active ingredient in Metamizol Basi, is a pyrazolone presented as an injectable solution for intramuscular and intravenous use. It treats acute pain, post‑operative pain, fever, and visceral pain in adult patients.

GNH India supplies Metamizol Basi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, clinics and procurement teams worldwide, ensuring consistent quality, regulatory compliance and batch‑tested documentation for global distribution.

Manufacturer / TM Owner

Laboratórios Basi – Indústria Farmacêutica, S.A.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Metamizole sodium is employed for managing pain and fever through its analgesic and antipyretic actions.
  • Acute pain: provides rapid relief of moderate to severe pain.
  • Post‑operative pain: reduces pain intensity after surgical procedures.
  • Fever: lowers elevated body temperature.
  • Visceral and colic pain: alleviates spasm‑related abdominal discomfort.

How It Works

  • Metamizole sodium exerts its effect by non‑selectively inhibiting cyclooxygenase enzymes, which reduces prostaglandin synthesis. The lowered prostaglandin levels diminish peripheral nociceptor sensitisation, while central actions on pain pathways and spasmolytic properties further contribute to analgesia and antipyresis.

Side Effects

Common Side Effects

  • Hypotension: transient drop in blood pressure after injection.
  • Nausea or vomiting: gastrointestinal upset.
  • Dizziness or vertigo: sensation of light‑headedness.
  • Injection site pain: local discomfort at the administration site.
  • Sweating: increased perspiration.
  • Headache: mild to moderate head pain.

Serious or Rare Side Effects

  • Agranulocytosis: severe reduction in white blood cells.
  • Stevens‑Johnson syndrome or toxic epidermal necrolysis: severe skin reactions.
  • Anaphylaxis: life‑threatening allergic response.
  • Severe hypotension: profound blood pressure fall requiring intervention.
  • Hepatic enzyme elevation: possible liver function abnormalities.
  • Blood dyscrasias: other serious hematologic abnormalities.

Precautions & Warnings

  • Metamizole sodium requires careful monitoring due to potential hematologic and cardiovascular effects.
  • Assess blood counts before therapy: monitor for agranulocytosis.
  • Use with caution in renal impairment: adjust monitoring of renal function.
  • Avoid in known hypersensitivity: discontinue if allergic reaction occurs.
  • Monitor blood pressure during IV infusion: watch for hypotensive episodes.
  • Pregnancy and lactation: use only if benefits outweigh potential risks.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Metamizole sodium may interact with several drug classes, requiring vigilance.

Major Interactions (Avoid)

  • Concurrent myelosuppressive agents: increased risk of bone‑marrow suppression.
  • ACE inhibitors: may potentiate hypotensive effects.
  • Other NSAIDs/COX inhibitors: additive renal toxicity risk.
  • Anticoagulants: heightened bleeding tendency.
  • Allopurinol: possible increased agranulocytosis risk.

Moderate Interactions (Monitor Closely)

  • Diuretics: monitor electrolytes and volume status.
  • Antihypertensives: observe for excessive blood‑pressure lowering.
  • CYP450 inhibitors: potential alteration of drug metabolism.
  • Other analgesics: enhanced sedation or respiratory depression.
  • Methotrexate: increased risk of toxicity, monitor levels.

Frequently Asked Questions

Metamizol Basi, containing metamizole sodium, is indicated for the relief of acute and post‑operative pain, reduction of fever, and treatment of visceral or colic pain. It is used in adult patients when rapid analgesia or antipyresis is required.

Metamizole sodium non‑selectively inhibits cyclooxygenase enzymes, decreasing prostaglandin synthesis. Lower prostaglandin levels reduce peripheral nociceptor sensitisation, while central actions on pain pathways and a spasmolytic effect contribute to its analgesic and antipyretic properties.

The dose of Metamizol Basi is determined by the prescribing clinician based on the patient’s condition, severity of symptoms, and route of administration. Healthcare professionals adjust the amount according to clinical guidelines and individual response.

Safety data for metamizole sodium in pregnancy and lactation are limited. It should only be used when the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Metamizole sodium belongs to the pyrazolone class and offers strong analgesic and antipyretic effects, often with a rapid onset. Compared with traditional NSAIDs, it may have a lower risk of gastrointestinal irritation but carries a distinct risk of agranulocytosis, which requires monitoring.

Metamizol Basi should be stored at 2‑8 °C, kept refrigerated, protected from light, and should not be frozen or shaken. Maintaining the cold chain preserves the stability and sterility of the injectable solution.

Metamizol Basi is supplied as an injectable solution for intramuscular or intravenous administration. The route, rate of infusion, and volume are determined by the prescriber, who follows aseptic technique and appropriate clinical protocols.

The most serious adverse reactions include agranulocytosis, severe skin reactions such as Stevens‑Johnson syndrome, anaphylaxis, and profound hypotension. Prompt recognition and immediate medical intervention are essential if any of these events occur.

Metamizol Basi should be avoided in individuals with known hypersensitivity to metamizole or other pyrazolones, in patients with existing severe blood‑cell disorders, and in those for whom the risk of agranulocytosis outweighs the therapeutic benefit.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Metamizole Sodium Monohydrate

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT